Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Andreas Helke who wrote (14538)	2/10/1998 7:24:00 PM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

I give some detailed responses a bit later. PIs do cause all kinds of metabolic problems, so it's hard to tell what was causing what in the press release. I was surprised that the two studies were so positive. APL is a special case where Panretin was expected to work. The KS data really opens things up. I'll give details later.

To: Andreas Helke who wrote (14538)	2/10/1998 8:22:00 PM
From: Hippieslayer	Respond to of 32384

I have heard it reported (Either LA TIMES OR WSJ or could have been on the TUBE) that the new protease inihibitors do cause large deposits of fat to occur in patients who take the drugs. I think it would be hard to determine if it is Panretin that's causing this unless they can do a Panretin study on KS patients sans the other drugs.